About ALK+ NSCLC

Starting a new treatment brings up a lot of questions. In addition to talking with your healthcare provider, this website is intended to help you understand your new therapy and what you may expect.

What Is ALK?

ALK+ NSCLC (anaplastic lymphoma kinase-positive non-small cell lung cancer) is a form of lung cancer that is caused by defects in the ALK gene and can be treated with drugs that target this gene.

Why Do I Need to Start a New Treatment?

Even with targeted treatments, ALK+ NSCLC can progress (worsen). Progression is when tumors grow, spread to other parts of the body (called metastasis), or when new tumors develop while on treatment.

Alternatively, some patients may not be able to tolerate treatments and your healthcare provider may recommend a new medication.

What Causes ALK+ NSCLC Progression?

While ALK-inhibitor treatment may initially work, eventually patients may experience disease progression. This progression may happen when the disease develops resistance, which can be caused by a number of different factors. One such factor is mutations in the ALK gene, which prevent the treatment from blocking the growth of cancer cells. This can cause the drug to stop working.

What Are the Common Sites of ALK+ NSCLC Progression?

Patients with ALK+ NSCLC may have their cancer spread to other parts of the body, including the liver, bone, and the brain.

It’s normal to have questions as you begin your treatment on ALUNBRIG®. We have additional resources for you to discuss with your healthcare provider as you get started. Learn More

Glossary

Metastasis
The spread of cancer from the original site to another part of the body.
Resistance
When cancer cells fail to respond to a drug used to destroy or weaken them. Drug resistance may happen at the beginning of a treatment, or may happen over time.

ALUNBRIG(TM) BRIGATINIB 39 mg TABLETS

This site is intended for residents
of the US and US territories only.

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib) and entering one that is not owned or controlled by Takeda Oncology.

Takeda Oncology makes no representation as to the accuracy of the information contained on sites we do not own or control. Takeda Oncology does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Cancel Continue >
Close

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib) and entering one that is not owned or controlled by Takeda Oncology.

This link will take you to the corporate ARIAD Pharmaceuticals, Inc. website.

Cancel Continue >
Close

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib).

This link will take you to another Takeda Oncology website.

Cancel Continue >
Close

The site you are about to enter is intended for US healthcare professionals only.

Please confirm that you are a US healthcare professional.

Yes, I confirm that I am a US healthcare professional Cancel
Close